Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SARomics Biostructures and Xbrane Bioscience Form a Strategic Partnership

Published: Thursday, January 30, 2014
Last Updated: Wednesday, January 29, 2014
Bookmark and Share
Strategic partnership to deliver “off-the-shelf” protein structure services.

SARomics Biostructures and Xbrane Bioscience have signed a strategic partnership for “off-the-shelf” protein structures. The two companies will combine their world leading expertise within their respective fields to deliver “off-the-shelf” protein structure services.

The “off-the-shelf” concept is a service product that simplifies and de-risks drug discovery activities. It is targeted towards structure-based design projects where protein structure information is used to accelerate the drug discovery process.

In an “off-the shelf” product, crystals suitable for X-ray crystallographic studies of the protein in question have already been obtained. In a service project the protein can thus, within a very short turn-around time, be co-crystallized with a customers' compounds, revealing the mode of interaction of the compound with the protein target without the necessity for the customer to build up the same expertise in-house.

In this partnership the advanced structural biology platform and expertise contributed by SARomics Biostructures will be used to produce, crystallize and determine the structure of a number of challenging proteins belonging to the epigenetic pathway.

Targeting proteins involved in epigenetic mechanisms (the cellular processes associated with the modification of chromatin) has emerged as an important new therapeutic opportunity for treating cancer, diabetes, inflammatory diseases and more.

Xbrane Bioscience will provide its world leading know-how and proprietary technology within protein expression in order to produce the selected “off-the-shelf” proteins.

Björn Walse, CEO of SARomics Biostructures, said “We are excited about the opportunity to work with Xbrane Bioscience on this frontline project that clearly leverages the competitiveness of both companies”.

“The agreement with SARomics is an important step for our growth strategy and gives us an opportunity to demonstrate our capabilities within optimization of protein production in E. coli”, says Siavash Bashiri, CEO at Xbrane Bioscience.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A New EU-Funded Industry-Academia Drug Discovery Partnership Targets Challenging Kinases
Industry and academia join to create the Translational Kinase Tumor Inhibitor Discovery Consortium.
Wednesday, April 10, 2013
SARomics Biostructures and Red Glead Discovery Enters into Drug Discovery Collaboration
The companies will perform a joint collaborative project with the goal of developing novel lead compounds against epigenetic pathway targets.
Thursday, October 25, 2012
SARomics Biostructures Brings in New Strategic Owners
Innovationsbron AB and LUIS AB are investing in and becoming new co-owners of the company.
Saturday, September 15, 2012
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!